rAd-IFNa/Syn3 Shows Promise in Relapsed, Refractory Bladder Cancer
Relapse is common for patients with HG non-muscle-invasive bladder cancer following BCG treatment.
rAd–IFNa/Syn3 demonstrated a favorable safety profile; although nearly all patients experienced an adverse effect (AE), no grade 4 to 5 AEs or AE-related discontinuations were reported. The most frequently reported AEs were micturition urgency, dysuria, fatigue, pollakiuria, hematuria, and nocturia.
The study authors conclude by noting that “a phase III trial of high-dose rAd–IFNa/Syn3, which provided longer median HG RFS and equivalent biosafety, is ongoing.”
- Shore ND, Boorjian SA, Canter DJ, et al. Intravesical rAd–IFNa/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study [published online August 23, 2017]. J Clin Oncol. doi: 10.1200/JOC.2017.72.3064